Thursday 21 November 2019
Home      All news      Contact us     
wn.com - 1 month ago

Phase III PEMPHIX Study Shows Genentech’s Rituxan (rituximab) Superior to Mycophenolate Mofetil in Patients With ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 14, 2019-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan ® (rituximab) compared to mycophenolate mofetil (MMF), in adults with moderate to severe pemphigus vulgaris (PV). The study met the primary endpoint at week 52 and demonstrated that Rituxan is superior to MMF, with 40.3% of patients treated with Rituxan achieving sustained complete remission (CR) without the use of steroids for 16 consecutive weeks or more, compared to 9.5% in the MMF arm (p lt;0.0001). All secondary endpoints were statistically significant in favor...


Latest News
Hashtags:   

Phase

 | 

PEMPHIX

 | 

Study

 | 

Shows

 | 

Genentech

 | 

Rituxan

 | 

rituximab

 | 

Superior

 | 

Mycophenolate

 | 

Mofetil

 | 

Patients

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Sources